Qiagen NV QGEN Profile, Company FAQs & Facts, Industry, Sector, Employee Strength

QIAGEN in 2022 reduced its plastic usage in transportation by 16.5%, nearly double the target for at least a 9% reduction. QIAGEN was listed in the Global Disability Equality Index for the first time in 2022 and will use the results to identify and implement specific actions to better promote equity in its workforce. The company also increased the participation of women in leadership roles from 28% in 2018 to 35% in 2022 and aims to achieve 36% or more by 2023.

After submitting your request, you will receive an activation email to the requested email address. You must click the activation link in order to complete your subscription. First-of-its-kind systematic review on the clinical relevance of test values from the QuantiFERON-TB Gold Plus TB1 and TB2 blood collection tubes has been published // Study including 4,050 subjects h…

What’s Happening with QGEN Stock Today

It has operations in the Americas, Europe, the Middle East, Africa, and Asia-Pacific. Our product portfolio supports our customers across the continuum of molecular testing in molecular diagnostics and life sciences. From the first important step of DNA, RNA and protein extraction from biological samples, to novel testing technologies targeting single or multiple molecular variants, and software to analyze and interpret molecular data to deliver valuable insights.

  • The firm assay technologies make these biomolecules visible and ready for analysis.
  • Reducing its plastic footprint is just one aspect of QIAGEN’s sustainability initiatives.
  • At the core of this strategy is a focus on five pillars of growth which are built on the company’s leadership in sample technologies, the first step in any laboratory process.
  • QIAGEN is targeting market segments with promising growth opportunities.
  • It works by identifying specific T-cells in individuals with infectious agent exposure.

QIAGEN currently expects about $20 million of sales from the Verogen portfolio in 2023, building on about $5 million of sales for QIAGEN in 2022 from the distribution agreement. Due to planned investments for commercialization and portfolio development, the transaction is expected to be dilutive to full-year 2023 adjusted EPS by about $0.03 per share and neutral to adjusted EPS in 2024. Human identification DNA techniques have evolved greatly over the past few decades, helping to meet huge challenges like in the aftermaths of wars and natural disasters, as well as to support advances in criminal justice. As just one example, Investing in streaming tv the International Commission on Missing Persons in the Netherlands to date has profiled more than 44,000 bone samples and made more than 18,000 identifications – all processed using QIAGEN chemistry and kits. For over two decades, QCI Interpret has combined the accuracy and consistency of QIAGEN’s proprietary expert (MD/PhD) curation with the superior efficiency of machine curation (AI-powered) to enable high-confidence variant interpretation and reporting. QIAGEN has been recognized for its ongoing commitment to sustainability and responsible business practices with a recent ESG rating upgrade from ISS-ESG.

The QIAwave DNA/RNA Mini Kit allows for simultaneous purification of genomic DNA and total RNA from each cell or tissue sample, with the purified DNA and RNA eluted separately. Qiagen NV (QGEN) stock is lower by -3.99% over the last 12 months, and the average rating from fundamental analysis of forex Wall Street analysts is a Buy. InvestorsObserver’s proprietary ranking system, gives QGEN stock a score of 21 out of a possible 100. A database of clinical trials planned, currently ongoing, completed, suspended, withdrawn, and terminated in countries around the world.

Sample Processing

A database of medical devices that are in the process to get approved for sale around the world. Devices that are in development, through to those in the approval process are included. Qiagen NV lost about one-fifth of its market value on Thursday after the Dutch biotechnology company said earlier this week that it would focus on its stand-alone business strategy, rejecting possible suitors. Shares of Mirati Therapeutics Inc. were up about 3% in premarket trading on Tuesday, the day after the company said it received an accelerated approval from the Food and Drug Administration for a treatment for some people… In 2017, QIAGEN acquired OmicSoft Corporation, a leading provider of highly curated public datasets. To opt-in for investor email alerts, please enter your email address in the field below and select at least one alert option.

MarketWatch

Market cap, also known as market capitalization, is the total market value of a company. It’s calculated by multiplying the current market price by the total number of shares outstanding. Qiagen NV shares plummeted more than 25% in late trading on Tuesday after the company announced that a strategic review had ended with a decision to not break up nor sell the business. News, testing solutions and stories covering global efforts in the fight against COVID-19.

NYSE: QGENQiagen Nv Stock

The independent rating agency has elevated QIAGEN’s rating from C+ to B-, reaffirming its “Prime” status and placing it among the top 10% of all companies in the “Health Care Equipment & Supplies” industry. QIAGEN’s ESG performance has also been acknowledged by other independent rating agencies. MSCI ESG Research gave QIAGEN a grade A in its rating, and Sustainalytics ESG Risk Ratings placed the company in the low-risk group. QIAGEN introduced measures in 2022 to ensure that its products are used ethically in accordance with its Human Rights Policy. Additionally, the company launched a new supplier policy that requires suppliers to meet the expectations on environmental protection, labor rights, health and safety, and corruption.

This tailored approach not only enhances patient outcomes, but also contributes to cost savings within the healthcare system. Managing CMV disease can be financially burdensome, and proactive testing helps to alleviate this burden by providing targeted care for those at risk. In early 2023, QIAGEN’s emissions reduction targets were validated by the Science Based Targets initiative (SBTi), positioning it among the few companies in its sector with a verified net-zero science-based target. The company has committed to achieving net-zero greenhouse gas (GHG) emissions by 2050, using 2020 as the base year. In 2022, QIAGEN made significant strides, reporting a 20% decrease in Scope 1 and 2 emissions and a 13% reduction in Scope 3 emissions compared to 2021. QIAGEN also surpassed its target for a 9% reduction in plastic usage, achieving a 16.5% decrease.

It stands for Earnings before Interest, Taxes, Depreciation, and Amortization. It attempts to reflect the cash profit generated by a company’s operations. 52 week low is the lowest price of a stock best forex indicators in the past 52 weeks, or one year. 52 week high is the highest price of a stock in the past 52 weeks, or one year. All market data (will open in new tab) is provided by Barchart Solutions.

At the core of this strategy is a focus on five pillars of growth which are built on the company’s leadership in sample technologies, the first step in any laboratory process. QIAGEN – which in the late 1990s launched the first commercial kits to purify DNA from forensic casework samples – already has a leading position in the HID / forensics market. QIAGEN’s sample collection and preparation kits, genetic testing analysis, and workflow automation products are used around the world by forensic science laboratories and criminal investigators. Reducing its plastic footprint is just one aspect of QIAGEN’s sustainability initiatives.

Explore our digital magazine full of customer stories and videos on scientific breakthroughs and healthcare advances. Learn about who we are and what we do to make improvements in life possible. Up to date protocols and list of COVID-19 testing and research solutions. Multiplex amplification for human ID, with CODIS and European standard markers. QIAGEN’s therascreen PDGFRA RGQ PCR kit approved in U.S. to aid in identifying patients with unresectable or metastatic gastrointestinal stromal tumors positive for the PDGFRA D842V mutation who may b…

AI-driven literature extraction for thousands of rare disease genes fortifies and extends QIAGEN’s proprietary, human-certified content, providing complete bibliographic coverage of the clinical exome… To help clinicians determine the right dosage of immunosuppressive drugs to prevent both organ rejection and post-transplant infections, the TSN recommends the use of QuantiFERON Monitor before and after surgery. Testing before a kidney transplant allows for corrective measures for patients found to have weak immune systems, while post-surgical testing would aid clinicians in adjusting the regime of immunosuppressive medication that is crucial after any transplant.

The products feature fewer components, waste tubes made from 100% recycled plastic, and suitable buffer concentrates in smaller bottles. More compact kits and new ways of packing them reduce the amount of cardboard needed for packaging. QCI Interpret continuously expands its global footprint and is adopted by an increasing number of programs and institutions. For example earlier this year, the Danish National Genome Center selected QCI Interpret for variant interpretation in oncology genome sequencing.